Daily Archives: April 1, 2020

Republicans are bailout hypocrites (letter to the editor) – SILive.com

Posted: April 1, 2020 at 3:42 am

Back in 2008, the U.S. economy was crumbling due to many homeowners not paying their mortgages on their homes, as well as that vast number of Americans filing for bankruptcy. Historians and economists call this the Great Recession, which was the worst financial crisis since the Great Depression.

Many Republicans opposed a fiscal stimulus. The most common reason was that it would grow an already large budget deficit, which would lay the foundation for the next recession. They argued the best stimulus would be to do nothing for the economy, and therefore, favored slashing government spending to reduce the impact on the budget. This same approach is exactly what FDR did in 1937, which led the recession of 1937-1938.

In 2008, Republicans denounced bailouts for private businesses that were done through TARP Troubled Asset Relief Program, which was the bailout that was designed to save the economy from the crisis that nearly brought on a second Great Depression. Although this was constructed and signed into law by President George W. Bush, Republicans blamed President Obama for any problem with this program.

Conservative economist Milton Friedman suggested that the Great Depression was the cause of the Federal Reserves mistake of allowing the money supply to drastically shrink, which created severe deflation in our economy. As a result, banks collapsed and those with deposits would lose everything in their accounts.

Friedman suggested that the Federal Reserve could have prevented this by buying up massive amounts of government bonds, which would pump cash into a deflated economy by increasing the money supply.

In 2008, Republican economist and Federal Reserve Chairman Ben Bernanke enacted the policies Friedman suggested. As a result, it was successful at preventing the banking system from collapsing, infused cash into a deflated economy, and prevented a second Great Depression.

Today, Republicans are pushing the massive $2 triilion stimulus to address the fallout from the coronavirus on the economy. A large portion of this stimulus is in the form of bailouts for large businesses and corporations, with very little, comparatively, going to the average working class American. However, Republicans said in 2008 that the TARP bailout of $700 billion was too expensive. Back in 2009, the Tea Party formed by Republicans in opposition to such bailouts, but are silent today.

Republicans have proven to be hypocrites about bailouts. You can even make the case that they have lied and changed their position when it suits them. For example, they are opposed to anything that grows the budget deficit when a Democrat is president, but largely grow the deficit when a Republican is president.

When Obama was in office, they opposed anything he did that wouldve grown the deficit, such as his $800 billion infrastructure stimulus, but favored Trumps $2 trillion tax cut and massive spending programs that are increasing the budget deficit by $1 trillion every year as far out as 2030.

(Dr. Joseph Frusci is a New Springville resident.)

Go here to see the original:

Republicans are bailout hypocrites (letter to the editor) - SILive.com

Posted in Republican | Comments Off on Republicans are bailout hypocrites (letter to the editor) – SILive.com

Republicans Could Kill Obamacare In the Middle of Coronavirus Recovery – Vanity Fair

Posted: at 3:42 am

Americas public health system, already stretched thin by the onset of the coronavirus pandemic, could look even shakier come spring 2021. According to the Daily Beast, 18 Republican attorneys general still plan to participate in a lawsuit that could repeal the Affordable Care Act within a year. Representatives for five of these attorneys general confirmed to the outlet that they remain committed to overturning Obamacare regardless of the pandemic, which continues to spread in the very states they preside over. Its always been a question of legality, not health care policy, a spokesperson for the Tennessee Attorney General argued.

This is not the first GOP attempt to weaken the law, and repealing Obamacare would have an enormous impact on the countrys public health system, pandemic or not. But, as the Daily Beast notes, the timing of the decisionpotentially during the recovery stagegives it a seismic significance. At least 20 million Americans covered by Obamacare will lose their coverage if the law is repealed. The only thing worse than a public health pandemic is a public health pandemic without health care, Democratic strategist Jesse Ferguson said. Two coronavirus cases mentioned in the articleone of a teenage boy who died after being turned away from a hospital because he didnt have insurance, another of an uninsured woman who, after going to the hospital for treatment, was billed $35,000give an early preview to what could become the new normal, depending on which way the Supreme Court rules.

At a Fox News Town Hall earlier this month, Donald Trump explained his administrations reasoning for following through with the case. We want to terminate Obamacare because its bad, he said, calling the law very defective. When asked by an audience member about the GOPs failure to come up with an alternativeNBC notes that Trump has not backed a specific plan since he failed to replace the act in 2017he first praised himself for [getting] rid of the individual mandate, which was the worst part of Obamacare and then claimed that we have many healthcare plans now where its 60 percent, even 65 percent less expensive than Obamacare. While Trump added that what wed like to do is totally kill it, he praised his administration for managing [the remaining portion] fantastically. The way to get you really fantastic healthcare, he told the audience member, is to win back the house, keep the Senate, keep the White House.

To no surprise, the former vice president continues to deride Trumps pursuit of the case. Yesterday, Joe Biden called the GOPs continued push unconscionable given that Americans are already afraid of the impact the deadly COVID-19 pandemic is having on their livesthey don't need the added stress of losing their health insurance. He again urged to drop the lawsuit, something he advocated for last week in a letter to Trump and other conservatives. NBC called Bidens health care plan Obamacare-plus, preserving the status quo while helping uninsured people buy coverage by boosting subsidies, and competing with private insurers with an additional public option.

Bernie Sanders, on the other hand, wants Medicare for All, which would upend the current system and provide the same plan to everyone regardless of their employment status. It is nearly impossible to believe that anyone can still think its acceptable to continue with a health care system that leaves tens of millions of people uninsured, Sanders said earlier this month while addressing the coronavirus outbreak. The cruelty and absurdity of that view is more obvious in the midst of this crisis than it has ever been.

More Great Stories From Vanity Fair

Trump Awakens to the COVID-19 Danger Could Wall Streets Coronavirus Tsunami Get Worse? Jared Kushner Told Trump the Coronavirus Was Fake News Tucker Carlson on How He Brought His Coronavirus Message to Mar-a-Lago The 12 Most Insane Moments From Trumps National Emergency Presser How a QAnon Coronavirus Conspiracy About Oprah Went Viral From the Archive: Inside the Week of Hurricane Katrina, Revealing the Foolishness, Fear, and Politics That Turned a Natural Disaster Into a Man-Made Catastrophe

Looking for more? Sign up for our daily Hive newsletter and never miss a story.

Read the original post:

Republicans Could Kill Obamacare In the Middle of Coronavirus Recovery - Vanity Fair

Posted in Republican | Comments Off on Republicans Could Kill Obamacare In the Middle of Coronavirus Recovery – Vanity Fair

Republicans targeting 2024 White House bid diverge from Trump on coronavirus – Washington Examiner

Posted: at 3:42 am

Prominent Republicans eyeing a 2024 White House bid have placed themselves at the epicenter of efforts to blunt the coronavirus pandemic, with some departing from President Trump by proposing an extended and more aggressive economic shutdown.

As Trump floats reopening a quarantined national economy by Easter, two Republican senators with presidential aspirations, Tom Cotton of Arkansas and Rick Scott of Florida, support tightening current restrictions and maintaining them for at least 30 days. Scotts eight-point plan would suspend domestic airline travel and place a moratorium on peoples monthly financial obligations. Cotton advocates nationwide shelter-in-place rules and is urging the administration to heed the recommendations of Anthony Fauci and other experts.

This is the stark truth: we have to arrest the spread of the China virus to get the economy back on its feet & get life back to something like normal, Cotton tweeted Tuesday. The same day, Trump began discussing the need to balance public health concerns properly with the damage to a stunted economy could have on the public's psyche.

Cotton and Scott are among a handful of potential 2024 presidential candidates who have sought to influence the federal governments response to the coronavirus. Others have been drafted, willingly or not, by virtue of their position in the Trump administration. Vice President Mike Pence was tapped to lead the White House pandemic task force; Secretary of State Mike Pompeo is running point as it relates to coordination and interaction abroad.

Marco Rubio of Florida, chairman of the Senate Small Business Committee and a potential 2024 contender, was the lead Republican negotiator of a bipartisan blueprint to rescue small businesses teetering on insolvency because of the pandemic. The measure was a critical component of the $2 trillion coronavirus relief package poised to clear Congress this week.

With thousands of businesses endangered and millions poised to lose their jobs, some Republican strategists believe GOP primary voters will reward, or punish, 2024 contenders based on how they responded to the economic fallout.

At the very least, some political professionals expect the coronavirus pandemic to affect how Republicans campaign, even if it does not substantially alter what primary voters are looking for in a successor to Trump.

As candidates fine-tune their resumes for 2024, expect them to find ways to prove they can be trusted to lead in times of turmoil, said Bruce Haynes, a former Republican campaign consultant who is now vice chairman of public affairs for the Washington firm Sard Verbinnen & Co., adding that it was possible voters might end up caring less about ideology and more about questions such as, Can they lead?

Nikki Haley immediately resigned from her position on the board of directors of Boeing in a protest over the airplane manufacturers request for federal assistance to help mitigate financial challenges caused by the onset of the coronavirus. Haley, the former governor of South Carolina and Trumps first ambassador to the United Nations, has used Twitter and her political nonprofit organization as platforms to push preferred policies for addressing the pandemic.

DONT bail out individual industries, pick winners and losers, or pass a bloated stimulus package, Haley tweeted.

A veteran Republican operative advising GOP congressional candidates on the 2020 ballot expressed surprise that more potential 2024 hopefuls have not joined Haley in opposing the corporate rescue package included in the coronavirus relief bill.

Most of the 2024 Republicans seem to have the herd mentality on the relief bills, the GOP operative said. I thought one or two might vote against the legislation and use that as a wedge in the future You supported bailing out corporations, and I did not. But no one has caved on that yet.

Visit link:

Republicans targeting 2024 White House bid diverge from Trump on coronavirus - Washington Examiner

Posted in Republican | Comments Off on Republicans targeting 2024 White House bid diverge from Trump on coronavirus – Washington Examiner

Lilly and Sitryx Sign $880 Million+ 5-Year Development Deal – BioSpace

Posted: at 3:41 am

Eli Lilly and Oxford, England-based Sitryx entered an exclusive global licensing and research collaboration. The two companies will work to develop up to four preclinical compounds discovered by Sitryx for autoimmune diseases.

Under the terms of the deal, Lilly is paying Sitryx $50 million up front. Lilly will also make a $10 million equity investment in the company. Sitryx will be eligible for development milestones up to $820 million, in addition to commercialization milestones and royalty payments in the mid- to high-single digits.

Sitryx grants Lilly exclusive, worldwide license to develop and commercialize up to four immunometabolism targeted compounds, including Sitryxs two lead projects. The partnership will run for five years, with Sitryx taking on drug discovery and Lilly paying for and handling clinical development and commercialization.

As Lilly seeks to develop new and unique medicines for people suffering with autoimmune diseases, we are actively exploring a variety of scientific approaches both in our own labs and with external partners, said Ajay Nirula, vice president of immunology at Lilly. Regulating the metabolism of immune cells is a promising approach to treating these diseases, and we look forward to working with the talented researchers at Sitryx to advance their novel immunometabolism targets.

Sitryx was founded in 2018 with seed funding from SV Health Investors and by six researchers in immunology and immuno-regulation: Houman Ashrafian (SV Health Investors), Luke ONeill (Trinity College Dublin), Jonathan Powell (Johns Hopkins), Jeff Rathmell (Vanderbilt University), Michael Rosenblum (University of California San Francisco) and Paul Peter Tak (formerly chief immunology officer, global development leader and senior vice president R&D Pipeline at GlaxoSmithKline; Amsterdam University Medical Centre). It raised $30 million in Series A funding from SV Health Investors, Sofinnova Partners, Longwood Fund and GlaxoSmithKline in 2018.

The scientific focus of the company is regulating cell metabolism to treat diseases.

We are excited to partner with Lilly, one of the global leaders in the field of immunology, to pursue the discovery of novel targets and the development of innovative therapies for autoimmune and inflammatory diseases in the fast-emerging area of immunometabolism, said Neil Weir, chief executive officer of Sitryx. This agreement is transformational for Sitryx and further validates the strength of our scientific expertise and that of our Founder network and the potential for Sitryx to become a leader in this field.

Yesterday, Lilly announced that the U.S. Food and Drug Administration (FDA) had approved its supplemental Biologics License Application (sBLA) for Taltz (ixekizumab) for the treatment of children ages six to 18 with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The application was based on a Phase III trial of 171 patients with moderate to severe plaque psoriasis. The trial had co-primary endpoints, including the proportion of patients hitting a 75% improvement on their Psoriasis Area and Severity Index Score (PASI 75) and a static Physicians Global Assessment of clear or almost clear skin at Week 12.

Due to limited pediatric psoriasis treatment options available, treating children and adolescents with moderate to severe plaque psoriasis can be challenging, said Stacie Bell, chief scientific and medical officer, National Psoriasis Foundation. Having more FDA approved pediatric psoriasis treatment options available is a positive step forward in helping relieve the burden of psoriasis for pediatric patients, their families and the health care providers that treat these young patients.

Read the original here:
Lilly and Sitryx Sign $880 Million+ 5-Year Development Deal - BioSpace

Posted in Psoriasis | Comments Off on Lilly and Sitryx Sign $880 Million+ 5-Year Development Deal – BioSpace

MicroRNA Signature May Predict Diagnosis and Treatment Response in Patients with PsA – Rheumatology Advisor

Posted: at 3:41 am

Compared with control participants, patients with psoriatic arthritis (PsA) display a significantly greater expression of 6 serum microRNAs (miRNAs), according to study results published in Journal of Rheumatology.1 In addition, baseline expression of certain serum miRNAs was associated with treatment response in patients with PsA.

Prior research has suggested that miRNA, small, noncoding RNA molecules, may serve as regulators in the pathogenesis of autoimmune diseases.2 The researchers sought to explore the relationship between serum miRNA levels and PsA.

Patients with PsA (n=31) were enrolled from outpatient rheumatology clinics at St Vincents University Hospital in Dublin, Ireland. All patients underwent baseline clinical and laboratory assessments, including quantification of C-reactive protein (CRP) levels and erythrocyte sedimentation rates (ESR). Follow-up visits were conducted at 3, 6, and 9 months after PsA treatment initiation. Patients were classified as either treatment responders or nonresponders according to the European League Against Rheumatism criteria. A cohort of healthy control participants (n=20) was enrolled from the community. All study participants underwent a peripheral blood draw; a focused immunology panel of 68 miRNAs of interest was analyzed for each serum sample. The miRNA that were differentially expressed between the 2 study groups were selected for further analysis. Area under the receiver operating characteristic curve (ROC) was used to assess the predictive capacity of each miRNA.

Of the identified miRNAs, 6 were significantly overexpressed in patients with PsA compared with control participants; the 6 miRNAs included miR-221-3p, miR-130a-3p, miR-146a-5p, miR-151-5p, miR-26a-5p (all P <.001), and miR-21-5p (P <.01). According to ROC analyses, miR-130a-3p and miR-26a-5p emerged as the strongest predictors of PsA vs healthy control participants, with area under the curve values of 0.866 and 0.894, respectively. When miRNA expression was compared with nonspecific markers of inflammation, including ESR and CRP, only miR-130a-3p (r=0.53; P =.004) and miR-146a-5p (r=0.41; P =.03) correlated with CRP.

In addition, no significant associations were observed between miRNAs and ESR, suggesting that the 6-miRNA signature was PsA-specific and not just a marker of inflammatory disease. In prospective analyses, greater baseline expression of miR-130a-3p (P <.01), miR-221-3p, miR-146a-5p, miR-151a-5p, and miR-26a-5p (all P <.05) was associated with PsA therapeutic response vs nonresponse. Expression profiles did not appear to differ between patients receiving biologic vs nonbiologic therapies. The ROC analysis identified miR-221-3p, miR-130-3p, and miR-146a-3p as the strongest predictors of therapeutic response, with AUC values of 0.747, 0.760, and 0.717 respectively.

The results describe a serum microRNA signature with high discriminative capacity between PsA and control participants, as well as moderate prognostic capacity for PsA treatment response. Further study of these biomarkers is necessary to elucidate the pathogenesis of PsA.

References

1. Wade SM, McGarry T, Wade SC, Fearon U, Veale DJ. Serum microRNA signature as a diagnostic and therapeutic marker in patients in patients with psoriatic arthritis [published online March 1, 2020]. J Rheumatol. doi:10.3899/jrheum.190602

2. Pauley KM, Cha S, Chan EKL. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun. 2009;32(3-4):189-194.

Follow this link:
MicroRNA Signature May Predict Diagnosis and Treatment Response in Patients with PsA - Rheumatology Advisor

Posted in Psoriasis | Comments Off on MicroRNA Signature May Predict Diagnosis and Treatment Response in Patients with PsA – Rheumatology Advisor